BACKGROUND/AIMS: Serum @entity5 markers were investigated as prognostic factors for recurrence in @entity1 with @entity356 . METHODOLOGY: Preoperative serum levels of @entity787 , CA72-4, CA19-9, TPA and @entity10224 were sampled in 196 @entity1 with @entity356 undergoing curative surgery. The results were compared with the clinical recurrence and various clinicopathological factors. RESULTS: CA72-4, @entity787 , CA19-9, TPA and @entity10224 had sensitivities of 16.4%, 31.4%, 16.1%, 31.6%, and 6%, respectively. Sensitivity of two combinations was as high as 56.5%. Seventy-seven @entity1 (39.9%) had clinical recurrence in the follow-up periods. For those with preoperatively elevated serum @entity5 markers, 38% (12/32) had CA72-4, 42% (13/31) had CA19-9, 48% (29/60) and had @entity787 , 54% (6/11) had @entity10224 , and 62% (37/61) had TPA, and remained disease-free. Univariate analysis showed that TNM staging, Tumor size, Borrmann classification of @entity5 growth, and preoperative serum CA72-4 level were correlated with recurrence of disease. Multivariate analysis showed that independent prognostic factor of recurrence was TNM staging (P = 0.0007). CONCLUSIONS: Preoperative serum CA72-4 level is correlated with @entity5 , but is not an independent predictor for clinical recurrence of disease in @entity1 with @entity356 that undergo surgery.

Comparison of serum CA72-4, @entity787 , TPA, CA19-9 and XXXX levels in @entity356 @entity1 and correlation with recurrence.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'staging of disease'] @entity787 :: ('1084', 'Gene') :: ['CEA'] @entity10224 :: ('94025', 'Gene') :: ['CA125'] @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric cancers']
@entity10224 :: (94025,Gene) :: ['CA125']
